Storage after reconstitution, and the evidence behind the numbers
A needle blunts on first use. Reuse is uncomfortable, and it is a documented contributor to lipohypertrophy.
Archive — June 2025
Page 2 of 5 of this archive, newest first.
The eighteenth month, and the conversation that should have happened in the third
The dose-response curve in this class flattens near its top. That has direct consequences for whether the final rung is worth climbing.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
Inspectors cite Calder Vale Peptides of Skipton over sterility assurance
The observation that closes a facility is rarely the dramatic one.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
What an 18% rise in coupling-reagent prices does to a 2 mg vial
Follow the resin, not the catalogue.
How a claim degrades between the bench and the listing
Every step between the laboratory report and the product page removes information, and the badge is the last step.
Hong Kong export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
Independent analysis puts a QST orforglipron lot at 98.0%, against 94.2% on the certificate
The report states the gradient, the wavelength and the integration threshold, which is more than most.
From the floor in Wuhan: 12 posters, one theme
Reported from the sessions, and from the two hours afterwards.
The 30-day notice: how a compounding wind-down works in Brazil
The document is four pages. Three of them are about dates.
Twenty-eight days is a number from somebody else’s product
An in-use period is established by a dedicated study on a specific formulation in a specific container at a specific concentration. Borrowing one from a marketed product is…
One method is one opinion
Where two methods disagree, the conservative convention is to report the lower figure. It is not universal, and whether a laboratory follows it belongs on the report.
Falling ferritin is not always falling iron
The panel drawn during a week of vomiting is measuring the vomiting.
VendorInvestigate result on a Changsha liraglutide lot lands 3.2 points above the supplier’s stated figure
A reminder that a purity figure is the output of a method, and that methods differ.
Calder Vale Peptides of Skipton enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
Saudi Arabia pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
The submitted sample: the weakest link in the whole system
Every third-party report in this market describes a sample somebody chose to send. That choice is outside the laboratory’s control and outside its records.
What the older diet-and-exercise trials found in the hip
A plausible mechanism, a measurable change, and no outcome data. This is what an open question looks like.
LEADER misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
From the floor in Tianjin: 9 posters, one theme
Reported from the sessions, and from the two hours afterwards.
The 27-day notice: how a compounding wind-down works in Brazil
The document is four pages. Three of them are about dates.
What a 32% rise in coupling-reagent prices does to a 10 mg vial
Follow the resin, not the catalogue.
What the trials counted as intolerance
Trial discontinuation figures are a floor, not an estimate: trial populations are supported in ways ordinary patients are not.
What changed at CPC in June, and what the company says prompted it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What the new Brazil guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
From the floor in Hong Kong: 5 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Japan declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
SURMOUNT-2 was built to answer the stopping question, and it did
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
Bacteriostatic water, sterile water, and the 0.9 per cent that makes the difference
We set out what is known, what is inferred and what is simply assumed about the fortnight after a vial is opened.
Assay against a standard, or area per cent: two different questions
We asked the four independent testing services what standards they run against and what suitability criteria they apply. The answers are printed.
STEP 8 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A supplier suspends shipping to France after 18 consecutive customs detentions
The route did not close because of a rule about peptides.
Halvard & Pike Apothecary of Portland, Maine enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
PeptideMeter result on a Hong Kong mazdutide lot lands 1.4 points above the supplier’s stated figure
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
Pancreatitis, obstruction, gallbladder: three things nausea can be
A small number of serious gastrointestinal events occur in people taking these drugs. Distinguishing them from the expected effect profile is the most consequential…
The dose that got you here and the dose that keeps you here
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
The 11-day notice: how a compounding wind-down works in Italy
The document is four pages. Three of them are about dates.
Nantong export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
Independent analysis puts a SGN semaglutide lot at 96.6%, against 94.9% on the certificate
The supplier confirmed the determination and supplied the method behind its own figure inside a week.